WO2021252782A1 - Methods for manufacturing viral vectors - Google Patents
Methods for manufacturing viral vectors Download PDFInfo
- Publication number
- WO2021252782A1 WO2021252782A1 PCT/US2021/036840 US2021036840W WO2021252782A1 WO 2021252782 A1 WO2021252782 A1 WO 2021252782A1 US 2021036840 W US2021036840 W US 2021036840W WO 2021252782 A1 WO2021252782 A1 WO 2021252782A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sptff
- viral vector
- filtration module
- kda
- filtration
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 143
- 239000013603 viral vector Substances 0.000 title claims description 136
- 238000004519 manufacturing process Methods 0.000 title description 15
- 239000000203 mixture Substances 0.000 claims abstract description 103
- 238000001914 filtration Methods 0.000 claims description 195
- 239000012528 membrane Substances 0.000 claims description 158
- 238000009295 crossflow filtration Methods 0.000 claims description 110
- 239000012510 hollow fiber Substances 0.000 claims description 69
- 210000004027 cell Anatomy 0.000 claims description 67
- 239000012465 retentate Substances 0.000 claims description 56
- 238000012545 processing Methods 0.000 claims description 32
- 239000013598 vector Substances 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 239000012466 permeate Substances 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 238000004587 chromatography analysis Methods 0.000 claims description 25
- 238000005498 polishing Methods 0.000 claims description 20
- 101710163270 Nuclease Proteins 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 14
- 108091033319 polynucleotide Proteins 0.000 claims description 13
- 102000040430 polynucleotide Human genes 0.000 claims description 13
- 239000002157 polynucleotide Substances 0.000 claims description 13
- 238000001042 affinity chromatography Methods 0.000 claims description 12
- 238000011026 diafiltration Methods 0.000 claims description 12
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 8
- 108091008034 costimulatory receptors Proteins 0.000 claims description 8
- 239000002699 waste material Substances 0.000 claims description 8
- 241000713666 Lentivirus Species 0.000 claims description 7
- 102000005962 receptors Human genes 0.000 claims description 7
- 108020003175 receptors Proteins 0.000 claims description 7
- 230000007423 decrease Effects 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 241000702421 Dependoparvovirus Species 0.000 claims description 5
- 102000004533 Endonucleases Human genes 0.000 claims description 5
- 108010042407 Endonucleases Proteins 0.000 claims description 5
- 108020005004 Guide RNA Proteins 0.000 claims description 5
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 230000007717 exclusion Effects 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 239000004055 small Interfering RNA Substances 0.000 claims description 5
- 108010075944 Erythropoietin Receptors Proteins 0.000 claims description 4
- 102100036509 Erythropoietin receptor Human genes 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000000447 dimerizing effect Effects 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 230000007246 mechanism Effects 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 3
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 3
- 239000003957 anion exchange resin Substances 0.000 claims description 3
- 239000003456 ion exchange resin Substances 0.000 claims description 3
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 3
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 2
- 108091092584 GDNA Proteins 0.000 claims description 2
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 claims 1
- 238000011080 single-pass tangential flow filtration Methods 0.000 description 256
- 238000000746 purification Methods 0.000 description 22
- 239000000047 product Substances 0.000 description 21
- 239000002245 particle Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 238000001471 micro-filtration Methods 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- 238000000108 ultra-filtration Methods 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- -1 feed Substances 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 238000001728 nano-filtration Methods 0.000 description 6
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 5
- 238000011210 chromatographic step Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 230000000712 assembly Effects 0.000 description 4
- 238000000429 assembly Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 239000004627 regenerated cellulose Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 102100038083 Endosialin Human genes 0.000 description 3
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 102000018146 globin Human genes 0.000 description 3
- 108060003196 globin Proteins 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- RJBDSRWGVYNDHL-XNJNKMBASA-N (2S,4R,5S,6S)-2-[(2S,3R,4R,5S,6R)-5-[(2S,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(E,2R,3S)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-5-amino-6-[(1S,2R)-2-[(2S,4R,5S,6S)-5-amino-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3-dihydroxypropyl]-4-hydroxyoxane-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H](CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)[C@H](O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@@H](CO)O[C@@]3(C[C@@H](O)[C@H](N)[C@H](O3)[C@H](O)[C@H](O)CO)C(O)=O)C(O)=O)[C@H]2O)[C@H](O)[C@H]1O)[C@@H](O)\C=C\CCCCCCCCCCCCC RJBDSRWGVYNDHL-XNJNKMBASA-N 0.000 description 2
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 2
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 2
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 description 2
- 108700012439 CA9 Proteins 0.000 description 2
- 102100038078 CD276 antigen Human genes 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 2
- 102100038449 Claudin-6 Human genes 0.000 description 2
- 108090000229 Claudin-6 Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 102000010956 Glypican Human genes 0.000 description 2
- 108050001154 Glypican Proteins 0.000 description 2
- 108050007237 Glypican-3 Proteins 0.000 description 2
- 101000884275 Homo sapiens Endosialin Proteins 0.000 description 2
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 2
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 description 2
- 101710145802 Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 description 2
- 108010010995 MART-1 Antigen Proteins 0.000 description 2
- 102100037020 Melanoma antigen preferentially expressed in tumors Human genes 0.000 description 2
- 101710178381 Melanoma antigen preferentially expressed in tumors Proteins 0.000 description 2
- 102000003735 Mesothelin Human genes 0.000 description 2
- 108090000015 Mesothelin Proteins 0.000 description 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 102100026181 Placenta-specific protein 1 Human genes 0.000 description 2
- 108050005093 Placenta-specific protein 1 Proteins 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102100037686 Protein SSX2 Human genes 0.000 description 2
- 101710149284 Protein SSX2 Proteins 0.000 description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 2
- 102100029198 SLAM family member 7 Human genes 0.000 description 2
- 102100033579 Trophoblast glycoprotein Human genes 0.000 description 2
- 101710190034 Trophoblast glycoprotein Proteins 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 208000026448 Wilms tumor 1 Diseases 0.000 description 2
- 102100022748 Wilms tumor protein Human genes 0.000 description 2
- 101710127857 Wilms tumor protein Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000013406 biomanufacturing process Methods 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 108010039524 chondroitin sulfate proteoglycan 4 Proteins 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000011062 flow through chromatography Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 238000011146 sterile filtration Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 239000013607 AAV vector Substances 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108010058905 CD44v6 antigen Proteins 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 101710120600 Cancer/testis antigen 1 Proteins 0.000 description 1
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 1
- 101710120595 Cancer/testis antigen 2 Proteins 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 102300047802 Cutaneous T-cell lymphoma-associated antigen 1 isoform 1 Human genes 0.000 description 1
- 101710144543 Endosialin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 101710116743 Ephrin type-A receptor 2 Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000903703 Homo sapiens B-cell lymphoma/leukemia 11A Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101600098482 Homo sapiens Cutaneous T-cell lymphoma-associated antigen 1 (isoform 1) Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101001005725 Homo sapiens Melanoma-associated antigen 10 Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101001052849 Homo sapiens Tyrosine-protein kinase Fer Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102000016200 MART-1 Antigen Human genes 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102100025049 Melanoma-associated antigen 10 Human genes 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 102220562136 Putative uncharacterized protein encoded by HEXA-AS1_E22A_mutation Human genes 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108010006700 Receptor Tyrosine Kinase-like Orphan Receptors Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100024537 Tyrosine-protein kinase Fer Human genes 0.000 description 1
- 235000019897 UltracelTM Nutrition 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000002869 anti-sickling effect Effects 0.000 description 1
- 229940124574 antisickling agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012501 chromatography medium Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000012538 diafiltration buffer Substances 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 108020005243 folate receptor Proteins 0.000 description 1
- 102000006815 folate receptor Human genes 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000009285 membrane fouling Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 102220149336 rs886059922 Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/02—Reverse osmosis; Hyperfiltration ; Nanofiltration
- B01D61/027—Nanofiltration
- B01D61/0271—Nanofiltration comprising multiple nanofiltration steps
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/02—Reverse osmosis; Hyperfiltration ; Nanofiltration
- B01D61/029—Multistep processes comprising different kinds of membrane processes selected from reverse osmosis, hyperfiltration or nanofiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/147—Microfiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/147—Microfiltration
- B01D61/1471—Microfiltration comprising multiple microfiltration steps
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/149—Multistep processes comprising different kinds of membrane processes selected from ultrafiltration or microfiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
- B01D63/028—Microfluidic devices comprising semi-permeable hollow fibre membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/08—Flat membrane modules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/26—Further operations combined with membrane separation processes
- B01D2311/2623—Ion-Exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/26—Further operations combined with membrane separation processes
- B01D2311/2688—Biological processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/26—Further operations combined with membrane separation processes
- B01D2311/2697—Chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/10—Cross-flow filtration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/16—Diafiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2317/00—Membrane module arrangements within a plant or an apparatus
- B01D2317/02—Elements in series
- B01D2317/022—Reject series
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2317/00—Membrane module arrangements within a plant or an apparatus
- B01D2317/02—Elements in series
- B01D2317/027—Christmas tree arrangements
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
Definitions
- the present disclosure relates to improved systems and methods for purifying and/or concentrating viral vectors. More particularly, the disclosure relates to improved systems and methods using single pass tangential flow filtration to purify and/or concentrate viral vector compositions.
- purification processes may also include ultracentrifugation, ion exchange, and affinity and size exclusion chromatography methods. These purification and/or concentration methods are slow, costly, and not easily amenable to large scale viral vector production for use in therapeutic products. Moreover, these methods are limited in their ability to continuously purify and/or concentrate vector being feed from a bioreactor comprising producer cells.
- the present disclosure generally relates, in part, to improved methods and systems for purification and concentration of viral vector compositions.
- the invention provides methods of purifying and/or concentrating viral vector compositions comprising single pass tangential flow filtration. More particularly, the methods and systems are useful for large scale production of viral vector compositions (e.g, continuous and/or batch fed production).
- a method of purifying and/or concentrating a viral vector composition comprising the steps of: (a) feeding a composition comprising a viral vector through an SPTFF system, the system comprising: (i) a feed pump; and (ii) an SPTFF filtration module, wherein the SPTFF filtration module purifies the viral vector composition; and (b) collecting a purified viral vector composition.
- the viral vector is derived from an adeno-associated virus or a lentivirus.
- the viral vector is derived from a lentivirus.
- the SPTFF system does not comprise an affinity chromatography component.
- the SPTFF system comprises one or more SPTFF filtration modules.
- the SPTFF filtration module(s) comprise three or more tangential flow filtration (TFF) cassettes or hollow fiber cartridges.
- the SPTFF filtration module(s) comprise four or more tangential flow filtration (TFF) cassettes or hollow fiber cartridges.
- the SPTFF filtration module(s) comprise five or more tangential flow filtration (TFF) cassettes or hollow fiber cartridges.
- the SPTFF filtration module(s) comprise six or more tangential flow filtration (TFF) cassettes or hollow fiber cartridges.
- the SPTFF filtration module(s) comprise seven or more tangential flow filtration (TFF) cassettes or hollow fiber cartridges. In some embodiments, the SPTFF filtration module(s) comprise eight or more, nine or more, ten or more, eleven or more, twelve or more, or thirteen or more, tangential flow filtration (TFF) cassettes or hollow fiber cartridges.
- the TFF cassettes comprise one or more flat sheet membranes.
- the hollow fiber cartridges comprise one or more hollow fiber membranes.
- the one or more membranes comprise an average molecular weight cut-off (MWCO) selected from the group consisting of: about 1 kDa, about 5 kDa, about 10 kDa, about 20 kDa, about 30 kDa, about 40 kDa, about 50 kDa, about 60 kDa, about 70 kDa, about 80 kDa, about 90 kDa, about 100 kDa, about 200 kDa, about 300 kDa, about 400 kDa, and about 500 kDa.
- the one or more membranes comprises an MWCO of about 30 kDa.
- the one or more membranes comprises an MWCO of about 300 kDa.
- two or more TFF cassettes or hollow fiber cartridges are configured for processing in parallel. In some embodiments, two or more TFF cassettes or hollow fiber cartridges are configured for processing in serial. In some embodiments, the TFF cassettes or hollow fiber cartridges are configured for processing in parallel and serial.
- the viral vector composition follows a flow path through the SPTFF system and/or SPTFF filtration module.
- the TFF cassettes or hollow fiber cartridges have an effective membrane area.
- the effective membrane area decreases along the flow path within the SPTFF filtration module.
- the system comprises (a) a viral vector composition feed flow rate entering the SPTFF filtration module and (b) a viral vector composition retentate flow rate exiting the SPTFF filtration module.
- the viral vector composition feed flow rate entering the SPTFF filtration module is at least about lOx greater than the viral vector composition retentate flow rate exiting the SPTFF filtration module.
- the viral vector composition retentate flow rate exiting the SPTFF filtration module is at least about lOx less than the viral vector composition feed flow rate entering the SPTFF filtration module.
- the SPTFF filtration module has an average transmembrane pressure (TMP) of about 10 psi or lower, about 9 psi or lower, about 8 psi or lower, about 7 psi or lower, about 6 psi or lower, about 5 psi or lower, about 4 psi or lower, about 3 psi or lower, or about 2 psi or lower.
- the SPTFF filtration module has an average transmembrane pressure (TMP) of about 5 psi or lower.
- the feed pump is positioned immediately before the SPTFF filtration module and continuous with the flow path.
- the system further comprises a retentate pump after the SPTFF filtration module(s) and continuous with the flow path.
- the system further comprises a waste or permeate pump.
- the SPTFF system does not comprise centrifugation.
- the viral vector composition is not recirculated through the SPTFF system, SPTFF filtration module(s), and/or any TFF cassettes or hollow fiber cartridges within the SPTFF filtration module(s).
- system further comprises a single-pass diafiltration (SPDF) component following the SPTFF filtration module(s).
- SPDF single-pass diafiltration
- the system further comprises a polishing chromatography component after the SPTFF filtration module(s).
- the polishing chromatography component comprises a hydrophobic interaction resin, a size exclusion resin, and/or an ion exchange resin.
- the polishing chromatography component comprises an anion exchange resin.
- the polishing chromatography component removes host cell protein and/or host gDNA from the viral vector composition.
- the SPTFF system further comprises a 0.22 mM final filter.
- the SPTFF system further comprises a mechanism to add a nuclease to the viral vector composition.
- the nuclease is added to the viral vector composition prior to feeding the viral vector composition through the SPTFF filtration module.
- the nuclease is added to the viral vector composition after the viral vector composition has passed through the SPTFF filtration module.
- the nuclease is a denarase DNA endonuclease or the like.
- the system further comprises a bioreactor.
- the bioreactor comprises viral vector producer cells.
- the viral vector producer cells are lentiviral vector producer cells.
- the producer cells are maintained in suspension.
- the producer cells are HEK 293 cells.
- the HEK 293 cells are HEK 293T or HEK 293F cells.
- the viral vector comprises a polynucleotide encoding a therapeutic protein.
- the therapeutic protein is an engineered ab TCR, an engineered gd TCR, a dimerizing agent regulated immunoreceptor complex (DARIC), a chimeric antigen receptor (CAR), a chimeric costimulatory receptor (CCR), a bispecific T cell engager (BiTE), a zetakine receptor, a b-globin protein, an ABCD1 polypeptide, an erythropoietin receptor or fragment thereof, an endonuclease, or a megaTAL.
- the viral vector comprises a polynucleotide encoding an shRNA, a shmiR, or a guide RNA.
- FIGS 1A and IB show schematics of a single pass tangential flow filtration (SPTFF) module having similarly sized tangential flow filtration (TFF) cassettes or hollow fiber cartridges configured for processing both in parallel and serially.
- SPTFF single pass tangential flow filtration
- TFF tangential flow filtration
- FIGS 2A and 2B show schematics of an SPTFF module having TFF cassettes or hollow fiber cartridges configured for processing serially and decreasing in effective membrane area along the flow path.
- FIG. 3 shows an illustrative schematic of an SPTFF system.
- Figure 4 shows an illustrative schematic of an SPTFF system having additional features and/or components.
- Figure 5A is a graph depicting concentration factors (volumetric, titer, and particle) and host cell protein (HCP) levels for various experiments using 300 kDa membrane filters in an SPTFF system utilizing TFF cassettes.
- Figure 5B is a graph depicting vector copy number (VCN) from cells transduced with concentrated lentiviral vectors produced using standard TFF and improved SPTFF systems/methods.
- VCN vector copy number
- the present disclosure generally relates, in part, to improved single pass tangential flow filtration (SPTFF) methods for purifying and concentrating viral vector compositions for use in the manufacturing of drug products.
- SPTFF single pass tangential flow filtration
- these methods are particularly suitable for use with large batch (e.g, bulk-fed) or continuous purification/concentration systems, e.g. , viral vector produced in bioreactors.
- a viral vector is produced using producer cells.
- the present inventors have discovered that use of an SPTFF system is surprisingly effective as the primary means for large batch or continuous purification/concentration of viral vector compositions compared to systems using industry standard capture or affinity chromatography. . Additionally, the present inventors have discovered that decreasing the transmembrane pressure (TMP) within a SPTFF system surprisingly results in improved purification and concentration of the viral vector composition.
- TMP transmembrane pressure
- a method for purifying and/or concentrating viral vector comprises the steps of: (a) feeding a composition comprising a viral vector through an SPTFF system, the system comprising: (i) a feed pump; and (ii) an SPTFF filtration module, wherein the SPTFF filtration module purifies the viral vector composition; and (b) collecting a purified viral vector composition.
- an SPTFF system for purifying and/or concentrating viral vector.
- a system comprises a feed pump and an SPTFF filtration module, wherein the SPTFF filtration module purifies the viral vector composition.
- a viral vector is derived from an adeno-associated virus (AAV) or a lentivirus.
- AAV adeno-associated virus
- the methods or SPTFF systems described herein are used as the primary means for the viral vector purification and concentration in manufacturing processes, particularly in large batch and/or continuous manner operations.
- the systems and methods described herein do not comprise a capture or affinity chromatography component or step.
- a viral vector composition is not recirculated through an SPTFF system or SPTFF filtration module.
- the methods contemplated herein do not comprise centrifugation.
- an SPTFF filtration module comprises four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, or thirteen or more tangential flow filtration (TFF) cassettes.
- an SPTFF filtration module comprises four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, or thirteen or more hollow fiber TFF cartridges.
- an TFF cassettes or hollow fiber TFF cartridges operate in serial and/or in parallel.
- the feed e.g, viral vector composition
- the feed can flow over one cassette or cartridge (or groups of cassettes or cartridges) at a time (a.k.a., serial operation), or be split between several cassettes or cartridges (a.k.a., parallel operation).
- the feed is split between several cassettes or cartridges in parallel (e.g, in a group or stage), and several groups of cassettes or cartridges are linked serially.
- TFF cassettes and/or hollow fiber TFF cartridges operating in serial and/or in parallel have an effective membrane area.
- the effective membrane area of a cassette or cartridge operating in serial mode would be equal to the size of the membrane.
- the effective membrane area of several cassettes or cartridges operating in parallel mode would have an effective membrane area equal to the sum of the membrane areas of all cassettes or cartridges at any given step along the flow path (see, e.g, Figures 1 A and IB).
- the effective membrane area decreases along the flow path within the SPTFF filtration module.
- the flow rate of a composition (e.g, the feed) entering an SPTFF filtration module is lOx greater than a retentate flow rate exiting the SPTFF filtration module. In some embodiments, a composition retentate flow rate exiting an SPTFF filtration module is lOx less than a feed flow rate entering the SPTFF filtration module.
- an SPTFF filtration module has an average transmembrane pressure (TMP) of about 10 psi or lower, about 9 psi or lower, about 8 psi or lower, about 7 psi or lower, about 6 psi or lower, about 5 psi or lower, about 4 psi or lower, about 3 psi or lower, or about 2 psi or lower.
- TMP transmembrane pressure
- a system comprises a feed pump, retentate pump, and/or a permeate/waste pump.
- the system further comprises a bioreactor, a single-pass diafiltration (SPDF) component, a polishing chromatography component, and/or a final filter.
- SPDF single-pass diafiltration
- a polishing chromatography component comprises a hydrophobic interaction resin, a size exclusion resin, and/or an ion exchange resin. In some embodiments, a polishing chromatography component comprises an anion exchange resin. In some embodiments, a bioreactor comprises producer cells. In some embodiments, the method further comprises the step of adding a nuclease to the composition.
- a viral vector comprises a polynucleotide encoding a therapeutic protein.
- a viral vector comprises a polynucleotide encoding an engineered ab TCR, an engineered gd TCR, a dimerizing agent regulated immunoreceptor complex (DARIC), a chimeric antigen receptor (CAR), a chimeric costimulatory receptor (CCR), a bispecific T cell engager (BiTE), a zetakine receptor, a chimeric TGFp receptor (CTBR), a b-globin protein, an ABCDl polypeptide, an erythropoietin receptor or fragment thereof, an endonuclease, or a megaTAL.
- a viral vector comprises a polynucleotide encoding an shRNA, a shmiR, or a guide RNA.
- Techniques for recombinant (/. ., engineered) DNA, peptide and oligonucleotide synthesis, immunoassays, tissue culture, transformation (e.g, electroporation, lipofection), enzymatic reactions, purification and related techniques and procedures may be generally performed as described in various general and more specific references in microbiology, molecular biology, biochemistry, molecular genetics, cell biology, virology and immunology as cited and discussed throughout the present specification. See, e.g. , Sambrook el al.
- an element means one element or one or more elements.
- the term “about” or “approximately” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.
- the term “about” or “approximately” refers a range of quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length ⁇ 15%, ⁇ 10%, ⁇ 9%, ⁇ 8%, ⁇ 7%, ⁇
- a range e.g, 1 to 5, about 1 to 5, or about 1 to about 5, refers to each numerical value encompassed by the range.
- the range “1 to 5” is equivalent to the expression 1, 2, 3, 4, 5; or 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or 5.0; or 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1,
- the term “substantially” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher compared to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.
- “substantially the same” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that produces an effect, e.g. , a physiological effect, that is approximately the same as a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.
- SPTFF filtration module refer to a component in an SPTFF system comprising one or more TFF cassettes or hollow fiber TFF cartridges.
- the SPTFF filtration module may also comprise a “holder” for the TFF cassettes.
- the SPTFF filtration module may also comprise one or more manifolds or manifold segments configured to carry a feed, retentate, permeate, and/or waste to and from the TFF cassettes and/or hollow fiber TFF cartridges.
- manifold segment refers to a block having a plurality of manifolds, including a manifold for carrying a feed, a manifold for carrying a retentate and a manifold for carrying a permeate.
- a “TFF cassette” or “cassette” refers to a plate-and-frame structure comprising a filtration membrane (e.g., an ultrafiltration membrane, a microfiltration membrane) and separate feed/retentate and permeate flow channels suitable for SPTFF processes.
- a filtration membrane e.g., an ultrafiltration membrane, a microfiltration membrane
- “hollow fiber TFF cartridge,” “hollow fiber cartridge” or “cartridge” refers to a structure (e.g, a tube-like structure) comprising channels formed by a bundle of hollow fibers (membranes). Such cartridges typically comprise capped ends, wherein the cartridge comprises an inlet for a feed sample or solution (e.g, a viral vector composition), and one or more separate outlets for the retentate and permeate.
- a feed sample or solution e.g, a viral vector composition
- high fiber membrane refers to a class of artificial filtration membranes containing a semi-permeable barrier in the form of a hollow fiber.
- filtration membrane refers to a selectively permeable membrane for separating a feed into a permeate stream and a retentate stream using an SPTFF process.
- Filtration membranes include, but are not limited to, ultrafiltration (UF) membranes, microfiltration (MF) membranes, reverse osmosis (RO) membranes and nanofiltration (NF) membranes.
- the filtration membrane may be a flat sheet or hollow fiber.
- microfiltration membranes and “MF membranes” refer to membranes that have pore sizes in the range between about 0.1 micrometers to about 10 micrometers.
- ultrafiltration membrane and “UF membrane” refer to a membrane that has pore sizes in the range of between about 10 nanometer to about 100 nanometers (i.e., about 0.01 micrometers to about 0.1 micrometers).
- nanofiltration membrane and “NF membrane” refer to membranes that have pore sizes in the range between about 1 nanometers to about 10 nanometers (i.e., about 0.001 micrometers to about 0.01 micrometers).
- Tangential flow filtration is a process that uses membranes to separate components in a liquid solution or suspension (e.g ., a feed sample) on the basis of size, molecular weight or other differences.
- a liquid solution or suspension e.g ., a feed sample
- the feed sample is pumped tangentially along the membrane surface and particles or molecules which are too large to pass through the membrane are retained and returned to a process tank for additional passes across the membrane (i.e., recirculation) until the feed sample is sufficiently clarified, concentrated, or purified.
- the cross-flow nature of TFF minimizes membrane fouling, thus permitting high volume processing per batch.
- SPTFF Single-Pass TFF
- SPTFF systems have not been used as the primary means to purify/concentrate viral particles in large scale biomanufacturing systems (e.g, large batch-fed or continuous viral vector production systems) because of the inherent difficulties in assembling SPTFF systems that can effectively purify/concentrate viral vectors to the high standards required for drug manufacturing. Moreover, it is difficult to create producer cells that can continually produce viral vectors for more than a few days (let alone weeks), which would enable the use of continuously- or large batch-fed SPTFF systems for purification/concentration of the viral vector. The present inventors have developed SPTFF systems and methods that are surprisingly effective for purifying/concentrating viral vectors (e.g, in a continuous- or large batch-fed manner), thus reducing costs, processing time, and product yield and recovery in viral vector manufacturing.
- improved systems and methods for purifying and/or concentrating viral vector compositions using single pass tangential flow filtration are provided.
- systems and methods contemplated herein are useful for the manufacturing of viral vector compositions in a continuous or large batch-fed manner.
- SPTFF system refers to a single pass tangential flow filtration (SPTFF) system that is configured for operation in a single-pass mode, i.e., wherein a feed sample (e.g, a viral vector composition) passes only once through the system, and is not recirculated through the system or SPTFF filtration module(s).
- a feed sample e.g, viral vector composition
- a feed sample is not recirculated through an SPTFF filtration module used for purification and/or concentration, but is recirculated through one or more TFF filtration modules used for other purposes, e.g, diafiltration.
- a feed sample e.g, viral vector composition
- a feed sample is not recirculated through any TFF filtration module within an SPTFF system.
- an SPTFF system for purifying and/or concentrating viral vector.
- a method comprises the steps of: (a) feeding a composition comprising viral vector through an SPTFF system, the system comprising: (i) a feed pump; and (ii) an SPTFF filtration module, wherein the SPTFF filtration module purifies the viral vector composition; and (b) collecting a purified viral vector composition.
- a viral vector is derived from an adeno-associated virus (AAV) or lentivirus.
- the viral vector is an anellovector.
- systems and methods contemplated herein do not comprise an affinity or capture chromatography component or step.
- a viral vector composition is not recirculated through an SPTFF system or the SPTFF filtration module.
- the method or system does not comprise centrifugation.
- an SPTFF system or related method may comprise different components (e.g, units and/or modules) to assist in processing.
- SPTFF systems useful for performing the methods contemplated herein can be assembled and operated using standard, existing TFF system components.
- TFF system components include, without limitation, one or more bioreactor(s), holding tank(s) or vessel(s), waste tank(s) or vessel(s), feed line(s), SPTFF filtration module(s), TFF cassette(s) comprising filtration membrane(s), cassette holder(s), hollow fiber cartridge(s), chromatography component(s), diafiltration component(s), ultrafiltration membrane(s)/filter(s), microfiltration membrane(s)/filter(s), conduits (e.g, tubing, piping) for feed, retentate and permeate, a housing or enclosure, valve(s), gasket(s), pump module(s) (e.g, pump module comprising a pump housing, diaphragm and check valve), sampling port(s), T-line(s) (e.g, for in-line buffer addition), valve sensor(s), flow meters(s), one or more reservoirs (e.g, bioprocess containers), pressure gauge(s), and vial filling component(s) (see, e
- one or more of the components are fluidly connected to effectuate continuous flow of the feed sample (e.g, viral vector composition) between components.
- the phrase “fluidly connected” refers to two or more components of an SPTFF system (e.g, two or more manifolds, two or more manifold segments, two or more TFF cassettes, two or more hollow fiber TFF cartridges, or any combination thereof), that are connected by one or more conduits (e.g, a feed channel, a retentate channel, a permeate channel) such that a feed sample can flow from one component to the other.
- processing refers to the act of filtering (e.g, by SPTFF) a feed stream containing a viral vector composition and subsequently recovering the viral vector in a concentrated and/or purified form.
- the concentrated viral vector can be recovered from the filtration system (e.g, an SPTFF system) in either a retentate stream or permeate stream depending on the size of the viral vector and the pore size of the filtration membrane.
- the viral vector is recovered from the filtration system in the retentate stream.
- purification refers to a procedure that enriches the amount of one or more components of interest (e.g, viral vectors) relative to one or more other components of a sample (e.g, host cell protein).
- the SPTFF systems contemplated herein removes host cell protein (HCP) from the composition — thereby reducing host cell protein concentration — while enriching for viral vectors.
- HCP host cell protein
- purification”, purify”, purified”, and “purifying” do not mean removing all material other than the component of interest from the sample.
- feed refers to the solution (e.g, viral vector composition) that is delivered to an SPTFF filtration module to be filtered.
- the feed that is delivered to an SPTFF filtration module for filtration can be, for example, feed from a feed container (e.g, vessel, tank, or bioreactor) external to or integrated within the SPTFF system.
- a feed container e.g, vessel, tank, or bioreactor
- filtration generally refers to the act of separating a feed sample into two streams, a permeate and a retentate, using membranes.
- permeate and “filtrate” refer to that portion of a feed that has permeated through a membrane.
- retentate refers to the portion of a feed that has been retained by a membrane, and a retentate is the stream enriched in a retained species.
- feed line or “feed channel” refers to a conduit for conveying a feed from a feed source (e.g, a feed container, vessel, tank, or bioreactor) to one or more processing components in a filtration assembly (e.g, an SPTFF system or SPTFF filtration module).
- a feed source e.g, a feed container, vessel, tank, or bioreactor
- processing components in a filtration assembly e.g, an SPTFF system or SPTFF filtration module
- retentate line or “retentate channel” refers to a conduit in a filtration assembly for carrying retentate.
- permeate line or “permeate channel” refers to a conduit in a filtration assembly for carrying permeate.
- SPTFF systems and related methods contemplated herein are useful for obtaining a purified and/or concentrated viral vector compositions suitable for in vitro and/or in vivo applications.
- purified and/or concentrated viral vector compositions are suitable for in vivo administration and/or manufacturing of gene therapy products, including but not limited to cellular gene therapy products and vaccines.
- purified and/or concentrated viral vector compositions are suitable for manufacturing of cellular therapies.
- purified and/or concentrated viral vector compositions are useful for gene therapy in vitro, ex vivo, or in vivo.
- SPTFF systems and related methods provided herein comprise one or more SPTFF filtration modules or components that are fluidly connected.
- an SPTFF system and related methods comprise a feed inlet on a first SPTFF filtration module and a retentate outlet on a last SPTFF filtration module.
- the first and last SPTFF filtration module are the same module, i.e., the system comprises only one SPTFF filtration module.
- SPTFF systems and related methods comprise one or more flow paths.
- flow path refers to a channel supporting the flow of a solution (e.g, feed, retentate, permeate, or composition) through all or part of an SPTFF system.
- an SPTFF system can have multiple flow paths, including a flow path through an entire system from a feed inlet to a retentate outlet, a flow path within an SPTFF filtration module (e.g, a flow path through TFF cassettes), a flow path between two or more adjacent SPTFF filtration modules (e.g, a flow path between manifold segments in adjacent SPTFF filtration modules), and a flow path between two or more adjacent TFF cassettes or hollow fiber cartridges (e.g, a flow path between manifold segments in adjacent SPTFF filtration modules).
- the flow path can have any topology which supports tangential flow (e.g, straight, coiled, arranged in zigzag fashion).
- the flow path can be parallel or serial.
- the flow path can be open, as in an example of channels formed by hollow fiber membranes, or have one or more flow obstructions, for example, of rectangular channels formed by flat-sheet membranes spaced apart by woven or non- woven spacers, or gaskets (e.g, silicone gaskets).
- gaskets e.g, silicone gaskets
- SPTFF systems and related methods comprise one or more bioreactors.
- SPTFF systems and related methods comprise one, two, three, four, or five, bioreactors.
- bioreactor refers to any manufactured or engineered device or system that supports a biologically active environment.
- a bioreactor is a vessel in which a cell culture process is carried out. Such a process may either be aerobic or anaerobic.
- Commonly used bioreactors are typically cylindrical, ranging in size from liters to cubic meters, and are often made of stainless steel.
- a bioreactor is made of a material other than steel and is disposable or single-use. It is contemplated that the total volume of a bioreactor may be any volume ranging from 100 mL to up to 10,000 Liters or more, depending on a particular process.
- the bioreactor is connected to a unit operation such as a depth filter.
- a bioreactor is used for both cell culturing as well as for precipitation, where a precipitant may be added directly to a bioreactor to precipitate one or more impurities.
- a bioreactor is fluidly connected to one or more components within an SPTFF system.
- a bioreactor is fluidly connected to an SPTFF filtration module.
- a bioreactor is fluidly connected to a holding tank or vessel, which may also be fluidly connected to an SPTFF filtration module (e.g, via a feed inlet).
- a bioreactor can be any type of bioreactor like a batch or a fed batch bioreactor or a continuous bioreactor like a continuous perfusion fermentation bioreactor.
- a bioreactor can be made of any suitable material and can be of any size. Typical materials are stainless steel or plastic.
- a bioreactor is a disposable bioreactor, e.g. , in form of a flexible, collapsible bag, designed for single-use. Cells growing in bioreactors may be submerged in liquid medium or may be attached to the surface of a solid medium. Submerged cultures may be suspended or immobilized.
- a bioreactor is fluidly connected to the SPTFF system.
- a bioreactor is fluidly connected to a holding tank (e.g, an intermediate holding tank).
- a bioreactor comprises producer cells.
- the terms “producer cells” or “producer cell line” refers to a cell or cell line which is capable of producing recombinant retroviral particles, comprising a packaging cell line and a transfer vector construct comprising a packaging signal.
- the production of infectious viral particles and viral stock solutions may be carried out using conventional techniques. Methods of preparing viral stock solutions are known in the art and are illustrated by, e.g, Y. Soneoka el al. (1995) Nucl. Acids Res. 23:628-633, andN. R. Landau etal. (1992 )J Virol. 66:5110-5113.
- Infectious virus particles may be collected from the producer cells using conventional techniques.
- the infectious particles can be collected by cell lysis, or collection of the supernatant of the cell culture, as is known in the art.
- the collected virus particles may be purified if desired. Suitable purification techniques are well known to those skilled in the art.
- producer cells are maintained in suspension within the bioreactor.
- producer cells are AAV vector producer cells, anellovector producer cells, or lentiviral vector producer cells.
- the producer cells are lentiviral vector producer cells.
- producer cells are HEK 293 cells.
- the HEK 293 cells are HEK 293T or HEK 293F cells.
- a viral vector comprises a polynucleotide encoding a therapeutic transgene or therapeutic protein.
- the first component in an SPTFF system or method is a bioreactor containing the starting material, e.g, culturing cells expressing a protein or viral vector to be purified.
- SPTFF systems useful for performing the methods contemplated herein further comprise one or more pumps.
- the pump is a feed pump.
- an SPTFF system comprises one or more feed pumps.
- the feed pump is positioned before the SPTFF filtration module(s) within the flow path.
- an SPTFF system or method comprises one or more retentate pumps.
- the retentate pump is positioned after the SPTFF filtration module(s) within the flow path.
- a retentate pump has a slower flow rate than a feed pump.
- an SPTFF system comprises one or more waste or permeate pumps.
- waste or permeate pumps have a slower flow rate than feed and/or retentate pumps.
- a feed flow rate entering an SPTFF filtration module is at least 7x greater than a retentate flow rate exiting the SPTFF filtration module.
- a feed flow rate entering an SPTFF filtration module is at least 8x greater than a retentate flow rate exiting the SPTFF filtration module.
- a feed flow rate entering an SPTFF filtration module is at least 9x greater than a retentate flow rate exiting the SPTFF filtration module. In some embodiments, a feed flow rate entering an SPTFF filtration module is at least lOx greater than a retentate flow rate exiting the SPTFF filtration module. In some embodiments, a feed flow rate entering an SPTFF filtration module is at least 1 lx greater than a retentate flow rate exiting the SPTFF filtration module. In some embodiments, a feed flow rate entering an SPTFF filtration module is at least 12x greater than a retentate flow rate exiting the SPTFF filtration module. In some embodiments, a feed flow rate entering an SPTFF filtration module is at least 7x to 12x greater than a retentate flow rate exiting the SPTFF filtration module.
- a composition retentate flow rate exiting an SPTFF filtration module is at least 7x less than a feed flow rate entering the SPTFF filtration module. In some embodiments, a composition retentate flow rate exiting an SPTFF filtration module is at least 8x less than a feed flow rate entering the SPTFF filtration module. In some embodiments, a composition retentate flow rate exiting an SPTFF filtration module is at least 9x less than a feed flow rate entering the SPTFF filtration module. In some embodiments, a composition retentate flow rate exiting an SPTFF filtration module is at least lOx less than a feed flow rate entering the SPTFF filtration module.
- a composition retentate flow rate exiting an SPTFF filtration module is at least 1 lx less than a feed flow rate entering the SPTFF filtration module. In some embodiments, a composition retentate flow rate exiting an SPTFF filtration module is at least 12x less than a feed flow rate entering the SPTFF filtration module. In some embodiments, a composition retentate flow rate exiting an SPTFF filtration module is at least 7x to 12x less than a feed flow rate entering the SPTFF filtration module.
- the present inventors also surprisingly discovered that a lower flow rate, and thus a lower transmembrane pressure, than suggested by certain third party providers/venders of TFF systems (including SPTFF systems), provided increased volumetric and product concentration factors for viral vector compositions.
- the required flow rate to yield a particular transmembrane pressure is the result of many factors including the total membrane area, membrane type, pore size, membrane flux, total length of the flow path, presence of additional pumps on the retentate and/or permeate lines, line clamps, etc.
- a feed pump has a flow rate of about 75 ml/min or less, about 100 ml/min or less, about 150 ml/min or less, about 200 ml/min or less, about 250 ml/min or less, about 300 ml/min or less, about 350 ml/min or less, about 400 ml/min or less, about 450 ml/min or less, or about 500 ml/min or less.
- a feed pump has a flow rate of about 75 ml/min to about 100 ml/min, about 75 ml/min to about 150 ml/min, about 75 ml/min to about 200 ml/min, about 75 ml/min to about 250 ml/min, about 75 ml/min to about 300 ml/min, about 75 ml/min to about 350 ml/min, about 75 ml/min to about 400 ml/min, about 75 ml/min to about 450 ml/min, or about 75 ml/min to about 500 ml/min.
- a feed pump has a flow rate of about 50 ml/min to about 100 ml/min, about 50 ml/min to about 150 ml/min, about 50 ml/min to about 200 ml/min, about 50 ml/min to about 250 ml/min, about 50 ml/min to about 300 ml/min, about 50 ml/min to about 350 ml/min, about 50 ml/min to about 400 ml/min, about 50 ml/min to about 450 ml/min, or about 50 ml/min to about 500 ml/min.
- a feed pump has a flow rate of about 25 ml/min to about 100 ml/min, about 25 ml/min to about 150 ml/min, about 25 ml/min to about 200 ml/min, about 25 ml/min to about 250 ml/min, about 25 ml/min to about 300 ml/min, about 25 ml/min to about 350 ml/min, about 25 ml/min to about 400 ml/min, about 25 ml/min to about 450 ml/min, or about 25 ml/min to about 500 ml/min.
- an SPTFF system and related methods comprises a clamp on the permeate line to decrease transmembrane pressure.
- the clamp is a partial clamp.
- the SPTFF system and related methods comprises a clamp on the retentate line to increase the transmembrane pressure.
- the clamp is a partial clamp. A partial clamp allows a reduced volume of retentate or permeate to flow through the clamped line.
- the feed stream flow (e.g, viral vector composition) across the membrane is not stopped to allow it to permeate or to diffuse backwards through the membrane by osmosis.
- SPTFF systems and related methods contemplated herein further comprise a holding tank or vessel.
- Holding tanks or vessels may be positioned in any position within the system where feed sample (e.g, viral vector composition) is to be retained prior to being fed into another component of the system.
- feed sample e.g, viral vector composition
- a system may comprise an intermediate holding tank designed to hold a viral vector composition prior to being fed into an SPTFF filtration module.
- Holding tanks or vessels may also be used to hold other components including, but not limited to, medias, buffers, and/or additives.
- SPTFF systems useful for performing the methods contemplated herein further comprise a mechanism to add a nuclease and/or buffer to a viral vector composition.
- the nuclease and/or buffer are held in a holding tank or vessel.
- the nuclease and/or buffer is added to the viral vector composition in an intermediate holding tank (see, e.g ., Figures 3 and 4).
- Trehalose or a poloxamer is added to the viral vector composition in the intermediate holding tank.
- the poloxamer is poloxamer 188.
- the intermediate holding tank is positioned before an SPTFF filtration module.
- the nuclease/buffer holding tank is fluidly connected to the intermediate holding tank.
- the SPTFF system comprises a filter (e.g, ultrafiltration membrane or microfiltration membrane) fluidly connected to the intermediate holding tank.
- the filter is fluidly connected to and between the nuclease/buffer holding tank and the intermediate holding tank.
- the nuclease is an endonuclease.
- the nuclease is derived from Serratia marcescens.
- the nuclease is a Denerase®.
- SPTFF systems useful for performing the methods contemplated herein further comprise a diafiltration component(s).
- the diafiltration component is a single pass diafiltration (SPDF) component.
- a diafiltration buffer e.g, formulation buffer
- the diafiltration component is positioned after an SPTFF filtration module.
- the diafiltration component comprises a TFF cassette or hollow fiber cartridge.
- SPTFF systems useful for performing the methods contemplated herein further comprise a chromatography component.
- the chromatography component is a polishing chromatography component and/or step.
- polishing chromatography refers to SPTFF system components, and related methods, which use chromatography to remove any remaining impurities or aggregates in a viral vector composition after the composition has passed through other purification/filtration steps (e.g, any SPTFF filtration modules/steps).
- the polishing chromatography component and/or method step comprises flow-through chromatography.
- flow-through chromatography refers a chromatography component, or related method step, for purifying or concentrating a product wherein a solution flows over a column which binds impurities while the desired product/molecule/vector does not substantially bind the column (i.e., flows through the column).
- a flow-through or polishing chromatography comprises one or more separation mechanisms to bind and remove impurities, including, but not limited to, ion exchange chromatography, size exclusion chromatography, or hydrophobic interaction chromatography, or a combination thereof.
- SPTFF systems and related methods comprise more than one polishing chromatography step. In some embodiments, SPTFF systems and related methods comprise two or more polishing chromatography steps. In some embodiments, SPTFF systems and related methods comprise three or more polishing chromatography steps. In some embodiments, SPTFF systems and related methods comprise one, two, or three polishing chromatography steps.
- SPTFF systems and related methods do not comprise a capture or affinity chromatography step or component as the primary purifying and/or concentrating step or component.
- the primary purifying/concentrating step is the first filtration step within a purification/concentration system or method.
- the SPTFF systems and related methods do not comprise a capture or affinity chromatography step or component as the first filtration step or component.
- the SPTFF systems and related methods do not comprise a capture or affinity chromatography step or component.
- capture chromatography or “affinity chromatography” refer to a chromatography component, or related method step, which involves binding and eluting of a desired product (e.g, viral particle) to and from a column.
- Capture or affinity chromatography typically uses selective non-covalent interactions between an analyte and specific molecule(s) (e.g, a specific ligand coupled to a chromatographic medium).
- capture or affinity chromatography may use protein G, an antibody, a specific substrate, ligand or antigen as the capture reagent.
- SPTFF systems and related methods contemplated herein comprise additional filters.
- the filter is a final filter (i.e., the last filter in the system or method). In some embodiments, the filter is a sterilization filter. In some embodiments, the filter comprises a microfiltration membrane. In some embodiments, the filter comprises an ultrafiltration membrane. In some embodiments, the filter comprises a nanofiltration membrane. In some embodiments, the filter is a 0.22 pm filter.
- SPTFF systems and related methods contemplated herein comprise a vial filling component and/or method step.
- SPTFF systems and related methods comprise one or more SPTFF filtration modules.
- the SPTFF filtration module comprises TFF cassettes and/or hollow fiber cartridges.
- the cassettes and/or cartridges are configured for processing 1) in parallel, 2) in series, or 3) both in parallel and in series (e.g, using valves, gaskets, diverter plates, manifolds, manifold segments, or and/or conduits).
- parallel processing refers to distributing a feed sample (e.g, a viral vector composition)in an SPTFF system to two or more filtration components (e.g, SPTFF filtration modules, TFF cassettes, hollow fiber cartridges) in the assembly concurrently for subsequent tangential flow filtration.
- a feed sample e.g, a viral vector composition
- two or more filtration components e.g, SPTFF filtration modules, TFF cassettes, hollow fiber cartridges
- serial processing refers to distributing a feed sample (e.g, a viral vector composition)in an SPTFF system to one filtration component (e.g, SPTFF filtration module, TFF cassette, hollow fiber cartridge) at a time, such that the retentate flow of a preceding component serves as the feed flow for a subsequent, adjacent component.
- a feed sample e.g, a viral vector composition
- one filtration component e.g, SPTFF filtration module, TFF cassette, hollow fiber cartridge
- the feed is split between several cassettes or cartridges in parallel (e.g, in a group or stage), and several groups of cassettes or cartridges are linked serially.
- cassettes or cartridges that are configured for processing in parallel precede the cassettes or cartridges that are configured for processing in series.
- all of the SPTFF filtration modules in an SPTFF system have cassettes that are configured for processing in parallel (e.g, one or more groups or stages of cassettes or cartridges configured in parallel and linked serially), except for the last two cassettes or cartridges, which are configured for processing in series (see, e.g, Figure 1A and IB).
- all of the SPTFF filtration modules in an SPTFF system have cassettes that are configured for processing in parallel (e.g, one or more groups or stages of cassettes or cartridges configured in parallel and linked serially), except for the last cassette or cartridge, which is configured for processing in series.
- the effective membrane area decreases along the flow path through the SPTFF filtration module.
- the term “effective membrane area” refers to the total area of the TFF membrane(s) at any given stage/point along the flow path within an SPTFF filtration module.
- the SPTFF filtration module comprises TFF cassettes or hollow fiber cartridges are configured for processing in parallel (see, e.g, stages 1-2 in Figure 1A, and stages 1-4 in Figure IB), then the effective membrane area is the sum of the membrane areas of all the cassettes or cartridges at any given stage or step along the flow path.
- the SPTFF filtration module has a flow path comprising 4 stages.
- the composition flows through three TFF cassettes or hollow fiber cartridges configured for processing in parallel.
- the effective membrane area at stage 1 is the sum of the membrane areas of all three TFF cassettes or hollow fiber cartridges.
- the composition flows through two TFF cassettes or hollow fiber cartridges configured for processing in parallel.
- the effective membrane area at stage 2 is the sum of the membrane areas of two TFF cassettes or hollow fiber cartridges.
- the composition flows through two single TFF cassettes or hollow fiber cartridges configured for processing serially.
- the effective membrane area at each of stages 3 and 4 equals the membrane area of each TFF cassete or hollow fiber cartridge. Accordingly, as shown in Figures 1 A and IB, the effective membrane area generally decreases along the flow path of the feed sample (e.g, viral vector composition) within an SPTFF filtration module.
- one or more TFF cassetes or hollow fiber cartridges may have different effective membrane areas and be assembled in decreasing order.
- the TFF cassetes or hollow fiber cartridges are configured for processing in serial and in decreasing order of effective membrane area at each stage.
- an SPTFF filtration module may comprise aspects of both systems shown in Figures 1 A-1B and Figures 2A-2B.
- the SPTFF filtration module comprises both TFF cassetes or hollow fiber cartridges having different effective membrane sizes and parallel assemble.
- the SPTFF filtration module comprises TFF cassetes or hollow fiber cartridges having different effective membrane sizes and assembled in parallel and in serial.
- one or more TFF cassetes and/or hollow fiber cartridges comprise an effective membrane area of about 0.01 m 2 , about 0.015 m 2 , about 0.02 m 2 , about 0.025 m 2 , about 0.03 m 2 , about 0.035 m 2 , about 0.04 m 2 , about 0.045 m 2 , about 0.05 m 2 , about 0.055 m 2 , about 0.06 m 2 , about 0.065 m 2 , about 0.07 m 2 , about 0.075 m 2 , about 0.08 m 2 , about 0.085 m 2 , about 0.09 m 2 , about 0.095 m 2 , about 0.1 m 2 , about 0.11 m 2 , about 0.12 m 2 , about 0.13 m 2 , about 0.14 m 2 , about 0.15 m 2 , about 0.16 m 2 , about 0.
- one or more TFF cassettes and/or hollow fiber cartridges comprise an effective membrane area of about 0.01 m 2 to about 10 m 2 , about 0.015 m 2 to about 10 m 2 , about 0.02 m 2 to about 10 m 2 , about 0.025 m 2 to about 10 m 2 , about 0.03 m 2 to about 10 m 2 , about 0.035 m 2 to about 10 m 2 , about 0.04 m 2 to about 10 m 2 , about 0.045 m 2 to about 10 m 2 , about 0.05 m 2 to about 10 m 2 , about 0.055 m 2 to about 10 m 2 , about 0.06 m 2 to about 10 m 2 , about 0.065 m 2 to about 10 m 2 , about 0.07 m 2 to about 10 m 2 , about 0.075 m 2 to about 10 m 2 , about 0.08 m 2 to about 10 ,
- one or more TFF cassettes and/or hollow fiber cartridges comprise an effective membrane area of about 0.01 m 2 , about 0.01 m 2 to about 0.015 m 2 , about 0.01 m 2 to about 0.02 m 2 , about 0.01 m 2 to about 0.025 m 2 , about 0.01 m 2 to about 0.03 m 2 , about 0.01 m 2 to about 0.035 m 2 , about 0.01 m 2 to about 0.04 m 2 , about 0.01 m 2 to about 0.045 m 2 , about 0.01 m 2 to about 0.05 m 2 , about 0.01 m 2 to about 0.055 m 2 , about 0.01 m 2 to about 0.06 m 2 , about 0.01 m 2 to about 0.065 m 2 , about 0.01 m 2 to about 0.07 m 2 , about 0.01 m 2 to about 0.075 m 2 , about 0.01
- the TFF cassettes and/or hollow fiber cartridges comprise an effective membrane area of 0.01 m 2 , 0.015 m 2 , 0.02 m 2 , 0.025 m 2 , 0.03 m 2 , 0.035 m 2 , 0.04 m 2 , 0.045 m 2 , 0.05 m 2 , 0.055 m 2 , 0.06 m 2 , 0.065 m 2 , 0.07 m 2 , 0.075 m 2 , 0.08 m 2 , 0.085 m 2 , 0.09 m 2 , 0.095 m 2 , 0.1 m 2 , 0.11 m 2 , 0.12 m 2 , 0.13 m 2 , 0.14 m 2 , 0.15 m 2 , 0.16 m 2 , 0.17 m 2 , 0.18 m 2 , 0.19 m 2 , 0.20 m 2 , 0.
- Membranes suitable for use in particular embodiments contemplated herein may be made of a variety of different substrates or polymers known in the art.
- the TFF cassettes or hollow fiber cartridges comprise membrane(s) made of polysulfone, polyethersulfone, poly(methyl methacrylate), polyvinylidene fluoride, modified cellulose, regenerated cellulose, delta regenerated cellulose, cellulose acetate, and/or other polymers or substrates known to those skilled in the art.
- the membrane is a polysulfone membrane.
- the membrane is a polyethersulfone membrane.
- the membrane is a poly(methyl methacrylate) membrane. In some embodiments, the membrane is a polyvinylidene fluoride membrane. In some embodiments, the membrane is a modified cellulose membrane. In some embodiments, the membrane is a regenerated cellulose membrane. In some embodiments, the membrane is a delta regenerated cellulose membrane.
- the membrane is a cellulose acetate membrane.
- a membrane comprises an average molecular weight cut-off (MWCO) of about 1 kDa, about 5 kDa, about 10 kDa, about 20 kDa, about 30 kDa, about 40 kDa, about 50 kDa, about 60 kDa, about 70 kDa, about 80 kDa, about 90 kDa, about 100 kDa, about 200 kDa, about 300 kDa, about 400 kDa, or about 500 kDa.
- the membrane comprises an average molecular weight cut-off (MWCO) of about 30 kDa.
- the membrane comprises an average molecular weight cut-off (MWCO) of about 300 kDa.
- the membrane comprises an average molecular weight cut-off (MWCO) of about 1 kDa to about 500 kDa. In some embodiment, the membrane comprises an average MWCO of about 5 kDa to about 500 kDa. In some embodiment, the membrane comprises an average MWCO of about 10 kDa to about 500 kDa. In some embodiment, the membrane comprises an average MWCO of about 20 kDa to about 500 kDa. In some embodiment, the membrane comprises an average MWCO of about 30 kDa to about 500 kDa. In some embodiment, the membrane comprises an average MWCO of about 40 kDa to about 500 kDa.
- MWCO average molecular weight cut-off
- the membrane comprises an average MWCO of about 50 kDa to about 500 kDa. In some embodiment, the membrane comprises an average MWCO of about 60 kDa to about 500 kDa. In some embodiment, the membrane comprises an average MWCO of about 70 kDa to about 500 kDa. In some embodiment, the membrane comprises an average MWCO of about 80 kDa to about 500 kDa. In some embodiment, the membrane comprises an average MWCO of about 90 kDa to about 500 kDa. In some embodiment, the membrane comprises an average MWCO of about 100 kDa to about 500 kDa. In some embodiment, the membrane comprises an average MWCO of about 200 kDa to about 500 kDa. In some embodiment, the membrane comprises an average MWCO of about 300 kDa to about 500 kDa. In some embodiment, the membrane comprises an average MWCO of about 400 kDa to about 500 kDa.
- the membrane comprises an average MWCO of about 1 kDa to about 5 kDa. In some embodiment, the membrane comprises an average MWCO of about 1 kDa to about 10 kDa. In some embodiment, the membrane comprises an average MWCO of about 1 kDa to about 20 kDa. In some embodiment, the membrane comprises an average MWCO of about 1 kDa to about 30 kDa. In some embodiment, the membrane comprises an average MWCO of about 1 kDa to about 40 kDa. In some embodiment, the membrane comprises an average MWCO of about 1 kDa to about 50 kDa. In some embodiment, the membrane comprises an average MWCO of about 1 kDa to about 60 kDa.
- the membrane comprises an average MWCO of about 1 kDa to about 70 kDa. In some embodiment, the membrane comprises an average MWCO of about 1 kDa to about 80 kDa. In some embodiment, the membrane comprises an average MWCO of about 1 kDa to about 90 kDa. In some embodiment, the membrane comprises an average MWCO of about 1 kDa to about 100 kDa. In some embodiment, the membrane comprises an average MWCO of about 1 kDa to about 200 kDa. In some embodiment, the membrane comprises an average MWCO of about 1 kDa to about 300 kDa. In some embodiment, the membrane comprises an average MWCO of about 1 kDa to about 400 kDa. In some embodiment, the membrane comprises an average MWCO of about 1 kDa to about 500 kDa.
- a membrane comprises an average pore size of about 0.01 pm, about 0.02 pm, about 0.03 pm, about 0.04 pm, about 0.05 pm, about 0.06 pm, about 0.07 pm, about 0.08 pm, about 0.09 pm, about 0.1 pm, about 0.15 pm, about 0.2 pm, about 0.25 pm, about 0.3 pm, about 0.35 pm, about 0.4 pm, about 0.45 pm, about 0.5 pm, about 0.55 pm, about 0.6 pm, about 0.65 pm, about 0.7 pm, about 0.75 pm, about 0.8 pm, about 0.85 pm, about 0.9 pm, about 0.95 pm, or about 1.0 pm.
- a membrane comprises an average pore size of 0.01 pm, 0.02 pm, 0.03 pm, 0.04 pm, 0.05 pm, 0.06 pm, 0.07 pm, 0.08 pm, 0.09 pm 0.1 pm, 0.15 pm, 0.2 pm, 0.25 pm, 0.3 pm, 0.35 pm, 0.4 pm, 0.45 pm, 0.5 pm, 0.55 pm, 0.6 pm, 0.65 pm, 0.7 pm, 0.75 pm, 0.8 pm, 0.85 pm, 0.9 pm, 0.95 pm, or 1.0 pm.
- a membrane comprises an average pore size of about 0.01 pm to about 1.0 pm, about 0.02 pm to about 1.0 pm, about 0.03 pm to about 1.0 pm, about 0.04 pm to about 1.0 pm, about 0.05 pm to about 1.0 pm, about 0.06 pm to about 1.0 pm, about 0.07 pm to about 1.0 pm, about 0.08 pm to about 1.0 pm, about 0.09 pm to about 1.0 pm, about 0.1 pm to about 1.0 pm, about 0.15 pm to about 1.0 pm, about 0.2 pm to about 1.0 pm, about 0.25 pm to about 1.0 pm, about 0.3 pm to about 1.0 pm, about 0.35 pm to about 1.0 pm, about 0.4 pm to about 1.0 pm, about 0.45 pm to about 1.0 pm, about 0.5 pm to about 1.0 pm, about 0.55 pm to about 1.0 pm, about 0.6 pm to about 1.0 pm, about 0.65 pm to about 1.0 pm, about 0.7 mih to about 1.0 mih, about 0.75 mih to about 1.0 mih, about 0.8 mih to
- a membrane comprises an average pore size of about 0.01 pm to about 0.02 pm, about 0.01 pm to about 0.03 pm, about 0.01 pm to about 0.04 pm, about 0.01 pm to about 0.05 pm, about 0.01 pm to about 0.06 pm, about 0.01 pm to about 0.07 pm, about 0.01 pm to about 0.08 pm, about 0.01 pm to about 0.09 pm, about 0.01 pm to about 0.1 pm, about 0.01 pm to about 0.15 pm, about 0.01 pm to about 0.2 pm, about 0.01 pm to about 0.25 pm, about 0.01 pm to about 0.3 pm, about 0.01 pm to about 0.35 pm, about 0.01 pm to about 0.4 pm, about 0.01 pm to about 0.45 pm, about 0.01 pm to about 0.5 pm, about 0.01 pm to about 0.55 pm, about 0.01 pm to about 0.6 pm, about 0.01 pm to about 0.65 pm, about 0.01 pm to about 0.7 pm, about 0.01 pm to about 0.75 pm, about 0.01 pm to about 0.8 pm, about 0.01 pm to about 0.85 pm,
- a membrane is a microfiltration membrane.
- a membrane is an ultrafiltration membrane.
- a membrane is a nanofiltration membrane.
- Exemplary TFF cassettes that are useful for the methods contemplated in particular embodiments herein include, but are not limited to, TFF cassettes supplied by Millipore Sigma Corporation (Burlington, Mass.), Pall Corporation (Port Washington, N.Y.), GE Healthcare Bio-Sciences (Piscataway, N.J.), and Sartorius AG (Bohemia, N.Y.)
- Exemplary MilliporeSigma Corporation TFF cassettes include, but are not limited to, Pellicon® cassettes (e.g ., Pellicon® 2 cassettes, Pellicon® 2 Mini cassettes, Pellicon® 2 Maxi cassettes, Pellicon® 3 cassettes) with BiomaxTM membrane, UltracelTM membrane or Durapore® membrane.
- Exemplary Pall Corporation TFF cassettes include, but are not limited to CentrasetteTM cassettes and CadenceTM single-use cassettes.
- Exemplary GE Healthcare Bio-Sciences TFF cassettes include, but are not limited to, KvickTM Flow cassettes.
- Exemplary Sartorius AG cassettes include, but are not limited to, Hydrosart® cassettes.
- An end plate or cassette holder is generally used to hold, or seal, the TFF cassettes in the SPTFF filtration module. The end plates and cassette holders can be fitted for use with particular cassettes.
- Examples of commercially-available end plates and cassette holders that are suitable for use in the SPTFF systems employed in the methods contemplated in particular embodiments herein include, but are not limited to, Pellicon® cassette holders (MilliporeSigma Corporation, Burlington, Mass.) such as, for example, Pellicon® 2 miniholders, acrylic Pellicon® holders, stainless steel Pellicon® holders, process scale Pellicon® holders.
- Other suitable cassette holders include, but are not limited to, CentramateTM TFF membrane cassette holders, CentrasetteTM TFF membrane cassette holders, MaximateTM TFF membrane cassette holders and MaxisetteTM TFF membrane cassette holders (Pall Corporation, Port Washington, N.Y.).
- existing cassette holders e.g ., Pellicon® cassette holders (Millipore Sigma Corporation)
- Pellicon® cassette holders can be modified to function in the SPTFF systems described herein for use in particular embodiments.
- Exemplary hollow fiber TFF cartridges useful in particular embodiments contemplated herein include, but are not limited to, hollow fiber cartridges supplied by Pall Corporation (Port Washington, N. Y.), GE Healthcare Bio-Sciences (Piscataway, N. J.), and Repligen Corporation (Waltham, M. A ).
- Exemplary Pall Corporation hollow fiber cartridges include, but are not limited to MicrozaTM cartridges.
- Exemplary GE Healthcare Bio-Sciences hollow fiber TFF cartridges include, but are not limited to, MaxCellTM cartridges, ProCellTM cartridges, MidGeeTM cartridges, XamplerTM cartridges, ReadyToProcessTM single-use cartridges, and various other laboratory and process scale cartridges.
- Exemplary Repligen Corporation hollow fiber cartridges include, but are not limited to, MicroKrosTM, MidiKrosTM, MidiKros TCTM, MiniKrosTM, KrosFloTM, or KrosFlow MaxTM cartridges.
- SPTFF system components can be disposable.
- Exemplary disposable components for SPTFF assemblies include, but are not limited to, components of Flexware® assemblies for Mobius® FlexReady Solution for TFF (MilliporeSigma Corporation, Burlington, Mass.).
- Other disposable components for SPTFF assemblies include, for example, components of AllegroTM TFF assemblies (Pall Corporation, Port Washington, N.Y.).
- TMP transmembrane pressure
- VCF volumetric and product concentration factors
- TMP transmembrane pressure
- SPTFF membrane pressure
- psi pounds per square inch
- An average TMP can be calculated by dividing the sum of the feed pressure entering into an SPTFF filtration module and the retentate pressure exiting the SPTFF filtration module by two; and subtracting the permeate pressure.
- TMP feed pressure + retentate pressure) / 2 - permeate pressure.
- volumetric concentration factor refers to the fold change (e.g, reduction) in volume.
- product concentration factof refers to the fold change (e.g, increase) in product concentration (e.g, viral particle concentration).
- PCF can be calculated by dividing the final product concentration by the initial product concentration.
- PCT final product concentration / initial product concentration.
- SPTFF filtration modules comprise a TMP of about 10 psi or lower, about 9 psi or lower, about 8 psi or lower, about 7 psi or lower, about 6 psi or lower, about 5 psi or lower, about 4 psi or lower, about 3 psi or lower, or about 2 psi or lower.
- the SPTFF filtration modules comprise an average TMP of about 10 psi or lower. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 9 psi or lower. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 8 psi or lower. In some embodiments, the SPTFF filtration comprise an average TMP of about 7 psi or lower. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 6 psi or lower. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 5 psi or lower. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 4 psi or lower. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 3 psi or lower. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 2 psi or lower.
- the SPTFF filtration modules comprise an average TMP of about 1 psi to about 10 psi. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 1 psi to about 9 psi. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 1 psi to about 8 psi. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 1 psi to about 7 psi. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 1 psi to about 6 psi. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 1 psi to about 5 psi.
- the SPTFF filtration modules comprise an average TMP of about 1 psi to about 4 psi. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 1 psi to about 3 psi. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 1 psi to about 2 psi.
- the SPTFF filtration modules comprise an average TMP of about 2 psi to about 10 psi. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 2 psi to about 9 psi. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 2 psi to about 8 psi. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 2 psi to about 7 psi. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 2 psi to about 6 psi. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 2 psi to about 5 psi.
- the SPTFF filtration modules comprise an average TMP of about 2 psi to about 4 psi. In some embodiments, the SPTFF filtration modules comprise an average TMP of about 2 psi to about 3 psi.
- the composition comprises one or more viral vectors encoding a therapeutic transgene or protein, e.g., a globin or an engineered antigen receptor.
- viral vectors include, but are not limited to vectors derived from: an adenovirus, an adeno-associated virus (AAV), a retrovirus, e.g. , a lentivirus (e.g, HIV-1, HIV-2), a herpes simplex virus e.g, HSV-1, HSV-2), anellovectors, or a vaccinia virus.
- the viral vector comprises a polynucleotide encoding a therapeutic transgene or therapeutic protein.
- the viral vector comprises a polynucleotide encoding a therapeutic protein.
- the viral vector comprises a polynucleotide encoding an engineered ab TCR, an engineered gd TCR, a dimerizing agent regulated immunoreceptor complex (DARIC), a chimeric antigen receptor (CAR), a chimeric costimulatory receptor (CCR), a bispecific T cell engager (BiTE), a zetakine receptor, a chimeric TGFp receptor (CTBR), a b-globin protein, an ABCD1 polypeptide, an erythropoietin receptor or fragment thereof, an endonuclease, or a megaTAL.
- DARIC dimerizing agent regulated immunoreceptor complex
- CAR chimeric antigen receptor
- CCR chimeric costimulatory receptor
- BiTE bispecific T cell engager
- CBR chimeric TGFp receptor
- b-globin protein an ABCD1 polypeptid
- a viral vector comprises a polynucleotide encoding a globin, a human globin, a human b-globin, a human d-globin, a human g-globin, a human anti-sickling b-globin, or a human b A T87 3 ⁇ 41oI> ⁇ h, a human p A - G16D/E22A 7Q -gi 0 bin, and a human b A
- a therapeutic protein is an engineered antigen receptor that binds a target antigen selected from the group consisting of: alpha folate receptor (FRa), anb6 integrin, B cell maturation antigen (BCMA), B7-H3 (CD276), B7-H6, carbonic anhydrase IX (CAIX), CCR1, CD 16, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8, CD70, CD79a, CD79b, CD123, CD133, CD135 (also known as fmc like tyrosine kinase 3; FLT3), CD 138, CD 171, carcinoembryonic antigen (CEA), Claudin-6 (CLDN6), C- type lectin-like molecule-1 (CLL-1), CD2 subset 1 (CS-1), chondroitin sulfate proteoglycan 4 (CSPG4), cutaneous T cell lymphoma-associated
- a viral vector comprises a polynucleotide encoding an shRNA, a shmiR, or a guide RNA.
- the shRNA, shmiR, or guide RNA bind a target sequence in a BCL11 A gene, e.g., a human BCL11 A gene.
- viral vectors are produced by producer cells comprising the accessory proteins to package the vector into a viral particle.
- the producer cells are maintained in suspension within a bioreactor.
- the producer cells are adherent producer cells.
- producer cells are HEK 293 cells.
- the HEK 293 cells are HEK 293T or HEK 293F cells.
- SPTFF single pass tangential flow filtration
- the material was slowly pumped into the SPTFF module, targeting a transmembrane pressure of 5 psi.
- Excess culture medium devoid of lentiviral vector, was collected into a waste container from the permeate lines and concentrated lentiviral vector was collected from the retentate line.
- the concentrated lentiviral vector was then filtered using a 0.22pm sterile filter to ensure sterility before vialing.
- SPTFF systems that were assembled and tested included additional diafiltration (e.g, using SPTFF and/or recirculating TFF) and polishing chromatography steps (e.g, size exclusion, hydrophobic interaction, and/or anion exchange chromatography) performed after SPTFF to further reduce unwanted impurities and properly formulate the lentiviral vector before final sterile filtration, as shown in Figure 4.
- additional diafiltration e.g, using SPTFF and/or recirculating TFF
- polishing chromatography steps e.g, size exclusion, hydrophobic interaction, and/or anion exchange chromatography
- Harvested cell culture medium containing lentiviral vector was collected from a stirred tank bioreactor containing modified HEK293 lentiviral vector producer cells. This material was then mixed thoroughly and split into several pools which were processed in parallel. Multiple pools were processed using the SPTFF purification process described in Example 1, while the final pool was processed using a standard vector purification process consisting of the following: clarification using a 0.45pm filtration, capture chromatography, recirculated tangential flow filtration to perform ultrafiltration and diafiltration, and a final 0.22pm sterile filtration.
- Each final lentiviral vector product was then used to transduce CD34+ cells which were then cryopreserved.
- the transduced cells were thawed and cultured for 14 days before harvesting and performing qPCR to determine the total vector copy number (VCN) per cell.
- the SPTFF process increased volumetric concentration, increased infectious titer (final titer / initial titer), increased viral particle concentration, and decreased host cell protein (HCP) levels.
- the SPTFF purification process increased the vector copy number of the drug product by 3-fold compared to the standard vector purification process.
- Harvested cell culture medium containing lentiviral vector was collected from a stirred tank bioreactor containing modified HEK293 lentiviral vector producer cells. This material was thoroughly mixed throughout the duration of processing using SPTFF. The material was pumped into the SPTFF module, gradually ramping up the flow rate until material began flowing out the retentate line. The volumetric concentration factors and transmembrane pressures were then recorded at each flow rate tested, as shown in Table 1. The retentate pools were subsequently tested for lentiviral vector content and product concentration factors were retroactively calculated from those values.
- Table 1 shows that, surprisingly, volumetric concentration factors increased with slower flow rates and product concentration factors increased along with it, up to a certain point.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Water Supply & Treatment (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Cell Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180038239.6A CN115698305A (en) | 2020-06-11 | 2021-06-10 | Method for producing viral vector |
US18/009,239 US20230212591A1 (en) | 2020-06-11 | 2021-06-10 | Methods for manufacturing viral vectors |
KR1020227040912A KR20230024891A (en) | 2020-06-11 | 2021-06-10 | Methods for making viral vectors |
EP21821063.1A EP4165197A4 (en) | 2020-06-11 | 2021-06-10 | Methods for manufacturing viral vectors |
CA3194520A CA3194520A1 (en) | 2020-06-11 | 2021-06-10 | Methods for manufacturing viral vectors |
JP2022572331A JP2023528776A (en) | 2020-06-11 | 2021-06-10 | Viral vector production method |
AU2021286651A AU2021286651A1 (en) | 2020-06-11 | 2021-06-10 | Methods for manufacturing viral vectors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063037777P | 2020-06-11 | 2020-06-11 | |
US63/037,777 | 2020-06-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021252782A1 true WO2021252782A1 (en) | 2021-12-16 |
Family
ID=78846581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/036840 WO2021252782A1 (en) | 2020-06-11 | 2021-06-10 | Methods for manufacturing viral vectors |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230212591A1 (en) |
EP (1) | EP4165197A4 (en) |
JP (1) | JP2023528776A (en) |
KR (1) | KR20230024891A (en) |
CN (1) | CN115698305A (en) |
AU (1) | AU2021286651A1 (en) |
CA (1) | CA3194520A1 (en) |
WO (1) | WO2021252782A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4252882A1 (en) * | 2022-03-31 | 2023-10-04 | Sartorius Stedim Biotech GmbH | Separation system for separating and purifying a target component |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050260672A1 (en) * | 2003-02-24 | 2005-11-24 | Gtc-Biotherapeutics, Inc. | Methods of tangential flow filtration and an apparatus therefore |
US20120219588A1 (en) * | 2008-09-24 | 2012-08-30 | Mark Thompson | Methods for purification of viruses |
US20170173537A1 (en) * | 2014-03-07 | 2017-06-22 | Agency For Science, Technology And Research | Apparatus and methods for fractionation of biological products |
WO2019236811A1 (en) * | 2018-06-08 | 2019-12-12 | Bristol-Myers Squibb Company | Single pass tangential flow filtration hybrid configurations for enhancing concentration of macromolecule solutions |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3014901B1 (en) * | 2013-12-17 | 2017-06-09 | Genethon | PROCESS FOR PURIFYING ENHANCED VIRUSES OR VIRTORS |
KR102079585B1 (en) * | 2014-08-29 | 2020-02-21 | 이엠디 밀리포어 코포레이션 | Single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate |
US20210198695A1 (en) * | 2018-08-16 | 2021-07-01 | Spacecraft Seven, Llc | Production methods for viral vectors |
-
2021
- 2021-06-10 AU AU2021286651A patent/AU2021286651A1/en active Pending
- 2021-06-10 JP JP2022572331A patent/JP2023528776A/en active Pending
- 2021-06-10 US US18/009,239 patent/US20230212591A1/en active Pending
- 2021-06-10 WO PCT/US2021/036840 patent/WO2021252782A1/en unknown
- 2021-06-10 KR KR1020227040912A patent/KR20230024891A/en active Search and Examination
- 2021-06-10 CA CA3194520A patent/CA3194520A1/en active Pending
- 2021-06-10 EP EP21821063.1A patent/EP4165197A4/en active Pending
- 2021-06-10 CN CN202180038239.6A patent/CN115698305A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050260672A1 (en) * | 2003-02-24 | 2005-11-24 | Gtc-Biotherapeutics, Inc. | Methods of tangential flow filtration and an apparatus therefore |
US20120219588A1 (en) * | 2008-09-24 | 2012-08-30 | Mark Thompson | Methods for purification of viruses |
US20170173537A1 (en) * | 2014-03-07 | 2017-06-22 | Agency For Science, Technology And Research | Apparatus and methods for fractionation of biological products |
WO2019236811A1 (en) * | 2018-06-08 | 2019-12-12 | Bristol-Myers Squibb Company | Single pass tangential flow filtration hybrid configurations for enhancing concentration of macromolecule solutions |
Non-Patent Citations (2)
Title |
---|
ANONYMOUS: "Viral vector", WIKIPEDIA, 10 March 2020 (2020-03-10), pages 1 - 8, XP055882948, Retrieved from the Internet <URL:https://en.wikipedia.org/w/index.php?title=Viral_vector&oldid=944914677> [retrieved on 20210820] * |
See also references of EP4165197A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4252882A1 (en) * | 2022-03-31 | 2023-10-04 | Sartorius Stedim Biotech GmbH | Separation system for separating and purifying a target component |
WO2023187064A1 (en) * | 2022-03-31 | 2023-10-05 | Sartorius Stedim Biotech Gmbh | Separation system for separating and purifying a target component |
Also Published As
Publication number | Publication date |
---|---|
EP4165197A1 (en) | 2023-04-19 |
EP4165197A4 (en) | 2024-07-03 |
US20230212591A1 (en) | 2023-07-06 |
KR20230024891A (en) | 2023-02-21 |
AU2021286651A1 (en) | 2023-01-19 |
JP2023528776A (en) | 2023-07-06 |
CA3194520A1 (en) | 2021-12-16 |
CN115698305A (en) | 2023-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Perry et al. | Lentiviral vector bioprocessing | |
Zydney | New developments in membranes for bioprocessing–A review | |
JP6936937B2 (en) | Manufacturing system, manufacturing equipment and manufacturing method for cells and / or cell products | |
US20130115588A1 (en) | Integrated bioreactor and separation system and methods of use therof | |
US20240150395A1 (en) | Continuous production of recombinant proteins | |
US20230212591A1 (en) | Methods for manufacturing viral vectors | |
Perry et al. | Insights into product and process related challenges of lentiviral vector bioprocessing | |
Berthold et al. | Interaction of cell culture with downstream purification: a case study | |
US20220340914A1 (en) | Methods of preparing viral vectors | |
US20210107938A1 (en) | Polypeptide separation method, polypeptide production method, and polypeptide purification device | |
CN115735006A (en) | Semi-automated hollow fiber system for viral transduction | |
US20240002770A1 (en) | Systems, apparatus, and methods for cell culture | |
US20240140989A1 (en) | A method and system for integrated and continuous viral filtration, concentration and buffer exchange | |
US20240139685A1 (en) | Systems and methods for single pass counter current diafiltration | |
Cruz et al. | Manufacturing of retroviruses | |
WO2024079608A1 (en) | Perfusion bioreactor tangential flow filtration | |
How | Body feed filtration provides enhanced bioprocessing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21821063 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022572331 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3194520 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021821063 Country of ref document: EP Effective date: 20230111 |
|
ENP | Entry into the national phase |
Ref document number: 2021286651 Country of ref document: AU Date of ref document: 20210610 Kind code of ref document: A |